RT Journal Article
SR Electronic
T1 Validation of “Days Alive and out of Hospital” as an Outcome Measure After Coronary Artery Bypass Graft Surgery, Acute Coronary Syndrome and Heart Failure Hospitalisation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.12.24302587
DO 10.1101/2024.02.12.24302587
A1 Grant, Robert
A1 Liao, Weiqi
A1 Miksza, Joanne
A1 Roman, Marius
A1 Murphy, Gavin
YR 2024
UL http://medrxiv.org/content/early/2024/02/13/2024.02.12.24302587.abstract
AB Background and Rationale ‘Days alive and out of hospital’ (DAOH) is a composite outcome measure that integrates several outcomes, including death, hospital length-of-stay, and hospital readmission. The minimum clinical important difference (MCID) in DAOH and its relation to clinically important long-term outcomes has not yet been studied for patients admitted to hospital for coronary artery bypass graft surgery (CABG), acute coronary syndrome (ACS), or heart failure (HF). We propose to determine whether differences in DAOH in common use as a MCID in clinical trials will be associated with significant differences in clinically important outcomes.Methods and Analysis This is a retrospective observational cohort study in three separate cohorts of adult (≥18 years) patients admitted to National Health Service (NHS) hospitals in England for: i) ACS ii) CABG iii) HF. Patients will be identified through Hospital Episode Statistics (HES) Admitted Patient Care (APC) data from 01/01/2009 – 31/12/2015 and followed up to 5 years after the index admission date.Adjusted and unadjusted multivariable fractional polynomial Cox regression models will be used to estimate HRs for primary outcomes, according to pre-specified differences in DAOH.Ethics and Dissemination This is a sub study of the observational cohort study ‘In Silico Trials of Surgical Interventions - Using Routinely Collected Data to Model Trial Feasibility and Design Efficiency In Vivo Randomised Controlled Trials’ - ClinicalTrials.gov Identifier: NCT05853536. Ethical approval has been obtained from University of Leicester Research Ethics Committee (22322-yll15-ls:cardiovascularsciences). Findings from this study will be disseminated through peer-reviewed scientific publications and research conferences.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Leicester NIHR Biomedical Research Centre, British Heart Foundation [CH/12/1/29419, AA18/3/34220].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the University of Leicester gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying this article were provided by NHS Digital under licence. The data that support the findings of this study are available from the corresponding author upon reasonable request. Raw data may be shared with permission of NHS Digital.